You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Halozyme reported third-quarter total revenue of $493 million, up 39%, and royalty revenue of $341 million, up 44%. It raised full-year 2026 guidance for total revenue, royalties, adjusted EBITDA and non-GAAP diluted EPS.
Halozyme Therapeutics said a Dutch patent court found MSD BV infringed one of its MDASE patents, barred Keytruda Qlex manufacturing and sales in specified European countries, and rejected MSD BV’s patent-invalidity arguments.
Halozyme Therapeutics, Inc. reported third-quarter revenue of $493 million, up 39%, and raised full-year 2026 total revenue guidance to $1.860 billion-$1.925 billion.
Halozyme Therapeutics, Inc. elected James Daly to its Board of Directors on September 28, 2026, with a term ending at the 2029 annual meeting of stockholders; he was not initially assigned to any Board committee.
Halozyme Therapeutics issued $1,500.0 million of 1.50% Convertible Senior Notes due 2033, receiving approximately $1,471.1 million net. It used approximately $187.5 million for capped calls and expects to repurchase approximately $151.7 million of 2027 Notes and $220.0 million of 2028 Notes.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Halozyme reported record Q2 2026 results with total revenue up 48% to $481 million and royalty revenue up 50% to $308 million, and raised full-year 2026 guidance across revenue, EBITDA, and EPS, driven by five new ENHANZE and Hypercon collaboration agreements signed year-to-date.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $328.8M | second quarter 2026 | — |
| EBITDA | $321.88M | Three Months Ended June 30, 2026 | — |
| Non-GAAP Diluted EPS non-GAAP | $2.28 | Three Months Ended June 30, 2026 | — |
| Non-GAAP Diluted Shares non-GAAP | 119.72M | Three Months Ended June 30, 2026 | — |
| Non-GAAP Net Income non-GAAP | $272.64M | Three Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HALO
this stock
Halozyme Therapeutics, Inc.
|
$11.43B | +49.0% | -52.0% | 25.1 | 12.0% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.56B | +18.8% | +46.2% | 34.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.84B | +23.8% | +20.8% | 21.1 | 2.1% |
|
MRNA
Moderna, Inc.
|
$90.38B | +657.4% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.05B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HALO | -3.2% | -17.7% | +45.9% | -23.4% | +49.0% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -5.8% | -16.5% | +45.4% | -23.2% | +38.4% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
